SCHEMBL25307104

SCHEMBL25307104

NC1CN(C(=O)CC2CC2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.45
NAMPT P43490 1/20 0.44
SMYD3 Q9H7B4 1/20 0.38
CYP1A2 P05177 1/20 0.36
CHRM4 P08173 1/20 0.36
TPSAB1 Q15661 1/20 0.36
TPSD1 Q9BZJ3 1/20 0.36
TPSG1 Q9NRR2 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
CHRNB2 P17787 2/20 0.34
CHRNA3 P32297 2/20 0.34
CHRNA4 P43681 2/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNB3 Q05901 1/20 0.34
CHRNA6 Q15825 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRL1 P41146 1/20 0.34
USP30 Q70CQ3 3/20 0.33
GNAI3 P08754 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL25300129 0.98 KDM1A (0.44) KDM1ANAMPTSMYD3CYP1A2CHRM4
SCHEMBL23019192 0.86 NAMPT (0.45) KDM1ANAMPTSMYD3CYP1A2CHRM4
SCHEMBL3401470 0.79
SCHEMBL13694472 0.77 NAMPT (0.47) KDM1ANAMPTSMYD3CYP1A2CHRM4
SCHEMBL1462662 0.75 CHRNB2 (0.63) NAMPTSMYD3CHRNB2CHRNA3CHRNA4
SCHEMBL14211316 0.75 CHRNB2 (0.60) NAMPTCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL29059752 0.75 ATM (0.44) KDM1ANAMPTSMYD3CYP1A2CHRM4
SCHEMBL14115752 0.74 GNAI3 (0.47) NAMPTTPSAB1TPSD1TPSG1GNAI3
SCHEMBL3203246 0.74 L3MBTL1 (0.46) KDM1ANAMPTKDM4EALDH1A1HSD17B10
SCHEMBL3203241 0.74 L3MBTL1 (0.46) KDM1ANAMPTKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115613-A1 DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2025-04-10 US disclosed
EP-4464700-A1 DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2024-11-20 EP disclosed
WO-2023134752-A1 DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR 武汉人福创新药物研发中心有限公司 2023-07-20 WO disclosed
CN-116444427-A Diaryl compounds for tubulin-SRC double-target inhibitor 武汉人福创新药物研发中心有限公司 2023-07-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115613-A1 DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR SRC, DSTYK, TUBB1 KDM1A 1037/4885NAMPT 1219/4885SMYD3 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.